A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

Inclusion Criteria: * Subject must be at least 18 years of age inclusive. * Subject must be HSV-2 seropositive * Subjects have a history of recurrent genital herpes in the past year * Subjects have a negative result on the HIV Ab/Ag assay * Subjects must agree to use contraception during study participation * Subjects must be willing NOT to use any topical genital therapy and systemic anti-HSV therapy from the beginning of the study till the end of week 16. * Subjects must be willing to collect a swab each day from their genital area (non-lesional as well as lesional, if appropriate) during the swabbing periods, which are 8 weeks prior to and upon the administration of study drug. * Female subjects must have a negative serum β-HCG at Screening and a negative urine pregnancy test prior to study drug administration. Exclusion Criteria: * Serious medical conditions, including poorly controlled diabetes, significant autoimmune diseases, co-existing sexually transmitted disease presentation (except HSV) in the anogenital area, etc. that may interfere with the assessment of the efficacy of UB-621. * Documented HSV resistance to acyclovir, valacyclovir, famciclovir, or penciclovir * History or current evidence of malignancy except for a localized non-melanoma skin cancer * Known immunosuppression * Exposure to HSV vaccine * Medical history of macular or maculopapular skin reactions to antibody (ie, as evidenced by IgG or plasma administration) * Any other conditions that in the j…